Rosuvastatin Reduces Vascular Inflammation and T-cell and Monocyte Activation in HIV-Infected Subjects on Antiretroviral Therapy-Reference-Cited by-同舟云学术

Rosuvastatin Reduces Vascular Inflammation and T-cell and Monocyte Activation in HIV-Infected Subjects on Antiretroviral Therapy

Published:2015-04-01 Issue:4 Volume:68 Page:396-404
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Funderburg Nicholas T.,Jiang Ying,Debanne Sara M.,Labbato Danielle,Juchnowski Steven,Ferrari Brian,Clagett Brian,Robinson Janet,Lederman Michael M.,McComsey Grace A.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference50 articles.

1. Inflammation, atherosclerosis, and coronary artery disease.;Hansson;N Engl J Med,2005

2. The immune system in atherosclerosis.;Hansson;Nat Immunol,2011

3. . Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.;Kuller;PLoS Med,2008

4. . Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.;Emery;J Infect Dis,2008

5. . Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy.;Kalayjian;J Infec Dis,2010

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological therapy targeting the immune response in atherosclerosis;International Immunopharmacology;2024-11

2. Atherosclerosis and Cardiovascular Complications in People Living with HIV: A Focused Review;Infectious Disease Reports;2024-09-01

3. Atherosclerosis and HIV: Exploring Cardiovascular Risks and Management;Cardiology in Review;2024-07-09

4. Primary Prevention of Cardiovascular Disease for People Living with Human Immunodeficiency Virus;Nursing Clinics of North America;2024-06

5. Chronic immune activation and accelerated immune aging among HIV-infected adults receiving suppressive antiretroviral therapy for at least 12 years in an African cohort;Heliyon;2024-06